IBEX Technologies Inc. (IBT.F)
| Previous close | 0.9600 |
| Open | 0.9600 |
| Bid | 0.0000 x 2500000 |
| Ask | 0.0000 x 2500000 |
| Day's range | 0.9600 - 0.9600 |
| 52-week range | 0.5200 - 0.9700 |
| Volume | |
| Avg. volume | 166 |
| Market cap | 23.527M |
| Beta (5Y monthly) | -0.05 |
| PE ratio (TTM) | 9.60 |
| EPS (TTM) | 0.1000 |
| Earnings date | 05 June 2024 - 10 June 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireIBEX Completes Sale of the Company
MONTRÉAL, April 08, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) announces that it has completed the sale of the company by amalgamating with 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited (“BBI”). In the amalgamation, BBI acquired all of the issued and outstanding shares of IBEX at a price of $1.45 per share in cash. The total consideration for the sale of IBEX was approximately $37.9 million. As pr
- GlobeNewswire
IBEX Shareholders Approve Sale of the Company
MONTRÉAL, Québec, April 03, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) is pleased to announce that at an annual and special meeting held today, IBEX shareholders approved the previously-announced proposed amalgamation (the “Amalgamation”) of IBEX and 15720273 Canada Inc., a newly-incorporated wholly-owned subsidiary of BBI Solutions OEM Limited (“BBI”), whereby BBI will acquire all of the issued and outstanding shares of IBEX at a price of $1.45
- GlobeNewswire
IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024
MONTRÉAL, March 22, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2024. “We were pleased to see revenues continue to increase as Q2 revenues were up 12% versus a year ago and the six-month revenues up 15%. The increase in revenues can mainly be attributed to the strong performance of customers in the hemostasis market” said Paul Baehr, President & CEO. N
